Cohance Life (COHANCE)
Slow GrowerFairStock Score: 44/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹440.65 |
| Market Cap | ₹16,859.15 Cr |
| P/E Ratio | 158.51 |
| ROCE | 14.89% |
| ROE | 16.51% |
| Dividend Yield | 0% |
| Profit Growth | -96.8% |
| Debt/Equity | 0.1 |
| Sales Growth | -23.1% |
| Free Cash Flow | ₹35 Cr |
| Promoter Holding | 57.49% |
| 52-Week Range | ₹266.7 — ₹875 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹102.03 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I wear Graham's defensive lens and Buffett's business-quality lens. Cohance has a low debt burden: Debt/Equity 0.10, ROE 16.51%, ROCE 14.89%, promoter holding 57.49%, positive FCF ₹35 Cr, Altman Z 4.32, and Piotroski 6/9. That tells me the balance sheet is not distressed and promoters have skin in the game. But the operating picture is poor: Sales growth -23.10%, profit growth -96.80%, and 5-year revenue CAGR only 7.51%. Latest quarter sales were ₹545 Cr and net profit ₹29 Cr. A ₹16,859 Cr market cap on that earnings base gives P/E 158.51, P/B 4.32, EV/EBITDA 41.32, and PEG 2.56. Even if margins recover, I am asked to pay a superlative price for a business that has not shown superlative growth. Graham Number is ₹104.77, so at ₹440.65 my margin of safety is -195.85%. DCF intrinsic value ₹0.28 is a warning that the given cash flows do not support the market price. FairStock 44/100 is mixed. The stock is down from ₹917.85 to ₹440.65, but cheapness is not the same as value; P/B 4.32 and P/E 158.51 are not defensive. I would wait for evidence that sales and profits have bottomed, and for price to approach a Graham-style valuation. A great balance sheet and low debt are not enough if the business is shrinking and the price already discounts a perfect recovery.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer